102
Participants
Start Date
December 31, 2006
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
corifollitropin alfa
Single injection of 100 μg corifollitropin alfa administered under protocol P05690
recFSH (follitropin alfa)
Daily recFSH administered under protocol P05690
gonadatropin releasing hormone (GnRH) antagonist ganirelix
GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
human chorion gonadatropin (hCG)
hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
progesterone
Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
placebo-recFSH (follitropin alfa)
Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
placebo-corifollitropin alfa
Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
open-label recFSH
Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
Organon and Co
INDUSTRY